Kidney International
Experimental study
Animals
Sodium-glucose co-transporter 2 inhibition improves age-dependent kidney microvascular rarefaction
23-Dec-2025
HH received research support from AstraZeneca and lecture honoraria from Alexion, Bayer Inc., and Vifor Pharma. HS received honoraria for presentations from AstraZeneca and GSK and consulting fees from Techspert. The sodium-glucose linked transporter 2 inhibitor, dapagliflozin, was generously provided by AstraZeneca; however, the company had no role in study design, data collection, analysis, interpretation, or manuscript preparation. All the other authors declared no competing interests.